SCHEMBL629227

SCHEMBL629227

O=C(O)Cc1csc(-c2cc(C(F)(F)F)ccc2Cl)n1

nearest known ligand 0.53

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
EIF4E P06730 4/20 0.53
KDM4E B2RXH2 4/20 0.50
LMNA P02545 2/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
SHMT1 P34896 4/20 0.48
SHMT2 P34897 3/20 0.48
HTT P42858 1/20 0.48
ALDH1A1 P00352 3/20 0.45
HPGD P15428 3/20 0.45
GAA P10253 2/20 0.45
RHOC P08134 1/20 0.44
RHOA P61586 1/20 0.44
HSD17B10 Q99714 1/20 0.44
TP53 P04637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16629821 0.82 CTSS (0.47) EIF4ELMNANPSR1ALDH1A1GAA
SCHEMBL10029576 0.81 KDM4E (0.51) EIF4EKDM4ELMNASMN1; SMN2SHMT1
SCHEMBL5025486 0.80 LMNA (0.72) KDM4ELMNASMN1; SMN2SHMT2HTT
SCHEMBL628055 0.80 LMNA (0.60) EIF4EKDM4ELMNASMN1; SMN2SHMT1
SCHEMBL18014768 0.80 NPSR1 (0.44) EIF4ENPSR1ALDH1A1RHOCRHOA
SCHEMBL627651 0.78 LMNA (0.59) KDM4ELMNASMN1; SMN2SHMT2HTT
SCHEMBL628748 0.78 LMNA (0.53) KDM4ELMNASMN1; SMN2SHMT1SHMT2
SCHEMBL26319542 0.77 ALDH1A1 (0.65) KDM4ELMNASMN1; SMN2SHMT1SHMT2
SCHEMBL866323 0.77 EIF4E (0.43) EIF4ESMN1; SMN2HTTALDH1A1
SCHEMBL627524 0.75 KDM4E (0.53) EIF4EKDM4ELMNASMN1; SMN2SHMT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102459203-A Compositions and methods for modulating retinol binding to retinol binding protein 4(RBP4) IRM LLC 2012-05-16 CN disclosed
US-20120077854-A1 COMPOSITIONS AND METHODS FOR MODULATING RETINOL BINDING TO RETINOL BINDING PROTEIN 4 (RBP4) IRM LLC (BM) 2012-03-29 US disclosed
US-20120077854-A1 COMPOSITIONS AND METHODS FOR MODULATING RETINOL BINDING TO RETINOL BINDING PROTEIN 4 (RBP4) IRM LLC (BM) 2012-03-29 US disclosed
EP-2419412-A1 COMPOSITIONS AND METHODS FOR MODULATING RETINOL BINDING TO RETINOL BINDING PROTEIN 4 (RBP4) IRM LLC (BM) 2012-02-22 EP disclosed
WO-2010120741-A1 COMPOSITIONS AND METHODS FOR MODULATING RETINOL BINDING TO RETINOL BINDING PROTEIN 4 (RBP4) IRM LLC (US) 2010-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120077854-A1 COMPOSITIONS AND METHODS FOR MODULATING RETINOL BINDING TO RETINOL BINDING PROTEIN 4 (RBP4) RBP4, RBP1, FABP4 EIF4E 2920/4885KDM4E 751/4885LMNA 1913/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.